Key Highlights

  • 4D Molecular Therapeutics CEO David Kirn sold 12,415 shares.
  • The sale was executed at a weighted average price of $10.05, generating proceeds of roughly $125,000.
  • Kirn still retains 871,737 shares following the transaction.
  • The sale is classified as a standard insider transaction unrelated to clinical developments or corporate performance.

4D Molecular Therapeutics (NASDAQ: FDMT) revealed that CEO David Kirn executed a sale of 12,415 shares at a weighted average price of $10.05, generating proceeds of roughly $125,000.

What Happened

The executive still retains 871,737 shares, with the divestment classified as a standard insider transaction unrelated to any immediate clinical developments or corporate performance milestones.

Market Reaction

The disclosed information does not include stock price or trading data for 4D Molecular Therapeutics following this insider transaction.

Outlook

The disclosed information does not indicate any change in corporate strategy or clinical program status tied to this routine insider sale.

How many shares did CEO David Kirn sell?

12,415 shares, at a weighted average price of $10.05, generating proceeds of roughly $125,000.

How many shares does Kirn retain after the sale?

871,737 shares.

Is this sale tied to any clinical or corporate developments?

No, it is classified as a standard insider transaction unrelated to any immediate clinical developments or corporate performance milestones.